CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.

Clinical Trial Description

Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages compared with conventional immunotherapy, especially in dealing with patients of hematologic malignancies and solid malignant tumors.This study design a novel specific Chimeric antigen receptor aiming at GD2 antigen.After CAR-T cell infusion,At periodic intervals, the investigators will evaluate clinical symptoms Improved conditions of this disease.Through this study,the investigators will evaluate the safty and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04406610
Study type	Interventional
Source	Fuda Cancer Hospital, Guangzhou
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	September 1, 2015
Completion date	October 15, 2016

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03796507` - Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation	Early Phase 1
Active, not recruiting	`NCT03665545` - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma	Phase 1/Phase 2
Active, not recruiting	`NCT03189420` - Glioma Microenvironment an Exploratory Study
Completed	`NCT03194906` - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors	Phase 2
Active, not recruiting	`NCT03739372` - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma	N/A
Completed	`NCT03779230` - Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse	Phase 1/Phase 2
Recruiting	`NCT03728673` - A Study Utilizing Escitalopram in Glioma Patients	Phase 2
Active, not recruiting	`NCT03496181` - Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
Recruiting	`NCT03180697` - The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas	N/A
Recruiting	`NCT03949192` - Efficacy of Kangliuwan for Recurrent Grade IV Glioma
Terminated	`NCT03927274` - Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma	Early Phase 1
Recruiting	`NCT03213002` - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM	Phase 1/Phase 2
Not yet recruiting	`NCT03763396` - Azoles Targeting Recurrent High Grade Gliomas	Early Phase 1
Terminated	`NCT03698201` - Blood Biomarker Signature in Glioma
Terminated	`NCT03436433` - Seizure Prophylaxis in Patients With Glioma or Brain Metastasis	Phase 2
Recruiting	`NCT03750890` - Visual Study of Molecular Genotype in Glioma Evolution
Enrolling by invitation	`NCT03102112` - Noninvasively Predicting Gene Status of Glioma	N/A
Active, not recruiting	`NCT03935685` - Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ	Phase 2
Completed	`NCT03834740` - A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection	Early Phase 1
Recruiting	`NCT03849430` - Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients